A Randomized, Multicenter, Open-label, Parallel Group Study in Postmenopausal Women With Osteoporosis to Evaluate the Noninferiority of Subject-administered Romosozumab via Autoinjector/Pen vs Healthcare Provider-administered Romosozumab via Prefilled Syringe
Phase of Trial: Phase III
Latest Information Update: 17 Oct 2019
Price : $35 *
At a glance
- Drugs Romosozumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 30 Jul 2019 Status changed from active, no longer recruiting to completed.
- 26 Apr 2019 Planned End Date changed from 12 Jul 2019 to 15 Jul 2019.
- 16 Oct 2018 Planned End Date changed from 4 May 2019 to 12 Jul 2019.